Melanoma In Situ
8
2
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
12.5%
1 terminated out of 8 trials
50.0%
-36.5% vs benchmark
13%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
BioMEL- Diagnostic and Prognostic Factors in Melanoma.
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms
Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm
Mohs and Immunofluorescence for Malignant Melanoma In Situ